Clinical Research on Moderately Hypofractionated Adaptive Postoperative Radiotherapy for High-Risk Endometrial Cancer

Launched by XIAORONG HOU · Aug 4, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a special type of radiation treatment called "moderately hypofractionated adaptive radiotherapy" for women who have high-risk endometrial cancer, which is cancer of the lining of the uterus. The goal is to see how well this treatment works after surgery, especially looking at side effects that happen soon after treatment and how it affects patients’ quality of life and cancer control over three years. The treatment involves carefully planned and adjusted radiation sessions to target the cancer area, sometimes combined with chemotherapy or another type of radiation called brachytherapy.

Women between 18 and 70 years old who have already had surgery to remove their uterus and ovaries, and who have certain types and stages of endometrial cancer, may be eligible. Participants need to be healthy enough to follow the radiation treatment plan and agree to take part in the study. During the trial, patients will receive the radiation treatment following a specific schedule and will be closely monitored for side effects, cancer control, and overall well-being. This study is currently recruiting patients and aims to help improve future care for women with this type of cancer.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Age : 18-70 years old.
• * Performance Status :
• • ECOG score 0-2.
• • Expected to comply with oART (Online Adaptive Radiotherapy) workflow.
• * Initial Surgical Treatment :
• • Total hysterectomy and bilateral salpingo-oophorectomy ± Pelvic and/or para-aortic lymph node dissection/sampling or sentinel lymph node biopsy.
• * Pathological Staging \& Histology (per FIGO 2009):
• Stage I :
• • Grade 3 endometrioid adenocarcinoma with superficial myometrial invasion and extensive LVSI (Lymphovascular Space Invasion).
• • Grade 2 endometrioid adenocarcinoma with deep myometrial invasion and extensive LVSI.
• • Grade 3 endometrioid adenocarcinoma with deep myometrial invasion. Stage II-IIIC1 : Endometrioid carcinoma. Stage I-IIIC1 : Serous carcinoma or clear cell carcinoma.
• * Informed Consent :
• • Patients and families fully understand the study protocol.
• • Voluntarily participate and sign informed consent forms before enrollment
• Exclusion Criteria:
• • Prior Radiotherapy : History of abdominal or pelvic irradiation.
• * Treatment Interval :
• • Without adjuvant chemotherapy: \>12 weeks between surgery and radiotherapy initiation.
• • With adjuvant chemotherapy: \>6 months between surgery and radiotherapy initiation.
• • Malignancy History : Prior diagnosis of other malignancies.
• • Pregnancy/Lactation : Pregnant or breastfeeding women.
• • Active Infection : Fever or uncontrolled active infection.
• • Inflammatory Bowel Disease (IBD) : History of IBD (regardless of activity status).
• • Comorbidities : Severe conditions affecting trial compliance, including: Unstable cardiac disease requiring treatment, renal impairment, chronic hepatitis, poorly controlled diabetes, psychiatric disorders